每經編輯｜每經實習記者 黃修眉     

◎每經實習(xi)記(ji)者 黃修眉(mei)

九九久（002411，前收盤價9.79元）今(jin)日公(gong)告稱，擬以7.8元/股，向新沂必康(kang)等(deng)6家公(gong)司發(fa)(fa)行不(bu)超過9億股，募資共(gong)(gong)70.2億元，用(yong)于收購陜西必康(kang)100%股份。并擬向李宗松等(deng)5名特定對象以8.39元/股，發(fa)(fa)行不(bu)超過2.77億股，總(zong)共(gong)(gong)募集不(bu)超過23.2億元的配套資金。

公告(gao)稱，擬(ni)并購(gou)陜(shan)西(xi)必(bi)康的股份來源為(wei)新(xin)沂(yi)必(bi)康、陜(shan)西(xi)北(bei)度(du)、陽光融匯、華夏人壽、上(shang)海萃(cui)竹、深創(chuang)投6家公司(si)，交(jiao)易標的資產估值70.2億元。擬(ni)定增對象為(wei)李宗松、周新(xin)基、陳耀民、薛(xue)俊、何(he)建東等5名特定對象，募(mu)集(ji)資金不超過(guo)本次交(jiao)易總額的25%。配套募(mu)集(ji)資金主要用于標的資產子公司(si)必(bi)康江蘇(su)的制藥生產線技改(gai)搬遷項(xiang)目(mu)。上(shang)述股份鎖(suo)定期為(wei)36個月。

本(ben)次(ci)交易(yi)(yi)前，上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)實(shi)際控(kong)(kong)制(zhi)(zhi)人(ren)為(wei)(wei)周新(xin)基。本(ben)次(ci)交易(yi)(yi)完成后，新(xin)沂必(bi)康將(jiang)持(chi)有公(gong)(gong)(gong)司(si)(si)(si)37.92%的(de)(de)股(gu)(gu)(gu)(gu)份(fen)，成為(wei)(wei)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)控(kong)(kong)股(gu)(gu)(gu)(gu)股(gu)(gu)(gu)(gu)東(dong)(dong)(dong)。陜(shan)西(xi)北(bei)度為(wei)(wei)新(xin)沂必(bi)康一(yi)(yi)致行動(dong)人(ren)，陽光融(rong)匯、華夏人(ren)壽(shou)、上(shang)(shang)海萃竹將(jiang)成為(wei)(wei)公(gong)(gong)(gong)司(si)(si)(si)持(chi)股(gu)(gu)(gu)(gu)5%以(yi)(yi)上(shang)(shang)的(de)(de)股(gu)(gu)(gu)(gu)東(dong)(dong)(dong)，上(shang)(shang)述5名(ming)交易(yi)(yi)對(dui)方(fang)將(jiang)成為(wei)(wei)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)關聯方(fang)；同時，本(ben)次(ci)配(pei)套(tao)(tao)融(rong)資(zi)的(de)(de)發(fa)(fa)行對(dui)象李(li)宗松通過控(kong)(kong)制(zhi)(zhi)新(xin)沂必(bi)康和(he)陜(shan)西(xi)北(bei)度間接(jie)控(kong)(kong)制(zhi)(zhi)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)39.50%的(de)(de)股(gu)(gu)(gu)(gu)份(fen)，并通過參與非公(gong)(gong)(gong)開發(fa)(fa)行股(gu)(gu)(gu)(gu)份(fen)募集資(zi)金(jin)直接(jie)持(chi)有上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)11.26%的(de)(de)股(gu)(gu)(gu)(gu)份(fen)，合計控(kong)(kong)制(zhi)(zhi)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)份(fen)達到(dao)50.75%，將(jiang)成為(wei)(wei)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)實(shi)際控(kong)(kong)制(zhi)(zhi)人(ren)。配(pei)套(tao)(tao)融(rong)資(zi)發(fa)(fa)行對(dui)象陳耀(yao)民在(zai)本(ben)次(ci)交易(yi)(yi)完成后將(jiang)成為(wei)(wei)實(shi)際控(kong)(kong)制(zhi)(zhi)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)份(fen)5%以(yi)(yi)上(shang)(shang)的(de)(de)股(gu)(gu)(gu)(gu)東(dong)(dong)(dong)，將(jiang)成為(wei)(wei)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)關聯方(fang)。《每日經(jing)濟(ji)新(xin)聞》記(ji)者注意到(dao)，九九久(jiu)是一(yi)(yi)家(jia)以(yi)(yi)醫(yi)藥中間體、農藥中間體和(he)新(xin)能(neng)源、新(xin)材料產(chan)業研發(fa)(fa)、加工和(he)生產(chan)為(wei)(wei)一(yi)(yi)體的(de)(de)技(ji)術業。停牌前總市(shi)(shi)值34.1億元，此次(ci)擬以(yi)(yi)不超過70.2億元并購陜(shan)西(xi)必(bi)康可謂“蛇吞象”。通過本(ben)次(ci)交易(yi)(yi)，在(zai)保留上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)現(xian)有精(jing)細化工和(he)新(xin)能(neng)源、新(xin)材料業務(wu)的(de)(de)同時，置(zhi)入(ru)盈利(li)能(neng)力較(jiao)強的(de)(de)，發(fa)(fa)展前景(jing)廣闊的(de)(de)醫(yi)藥類資(zi)產(chan)，從根本(ben)上(shang)(shang)改善公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)經(jing)營狀況(kuang)，增強公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)持(chi)續盈利(li)能(neng)力和(he)發(fa)(fa)展潛力，提高公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)資(zi)產(chan)質(zhi)量，以(yi)(yi)實(shi)現(xian)上(shang)(shang)市(shi)(shi)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)東(dong)(dong)(dong)的(de)(de)利(li)益最大化。